Himax Technologies Invests in Obsidian Sensors-March 2024-www.financetom.com

Himax Technologies Invests in Obsidian Sensors

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Himax Technologies Invests in Obsidian Sensors

May 29, 2024 3:41 AM

06:17 AM EDT, 05/29/2024 (MT Newswires) -- Himax Technologies ( HIMX ) said Wednesday that it has made a strategic investment in thermal imaging sensors provider Obsidian Sensors.

Himax ( HIMX ) said it is the lead investor in Obsidian's convertible note financing.

The investment's details were not disclosed.

Previous page： Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion Next page： Nasdaq re-enables routing for Members Exchange

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion

May 28, 2024

09:06 AM EDT, 05/28/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) announced Tuesday it has agreed to acquire the rights to NM26, an experimental eczema treatment, from Numab Therapeutics for $1.25 billion in an all-cash deal. Price: 147.06, Change: +0.09, Percent Change: +0.06 ...

Nasdaq re-enables routing for Members Exchange

May 28, 2024

May 28 (Reuters) - Nasdaq said on Tuesday it had re-enabled routing for exchange operator Members Exchange after disabling it for a brief period. The exchange operator had disabled the routing as of 7:36 a.m. ET and re-enabled it as of 8:54 a.m. ET, it said. ...

Nike partially wins appeal over stripes dispute with Adidas in Germany

May 28, 2024

BERLIN (Reuters) - Nike ( NKE ) can put three stripes on some of its trouser designs in Germany, a court ruled on Tuesday, in a second appeal hearing pitting the U.S. sports apparel maker against its smaller rival Adidas. The Duesseldorf regional court had already prohibited the U.S. firm from using two or three stripes on five of its...

Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD

May 28, 2024

09:16 AM EDT, 05/28/2024 (MT Newswires) -- Outlook Therapeutics ( OTLK ) said Tuesday that the European Commission has granted marketing authorization for Lytenava, the biopharmaceutical company's ophthalmic formulation of bevacizumab, to treat wet age-related macular degeneration in the EU. This is a landmark milestone for us, President and Chief Executive Russell Trenary said in a statement. The EU represents...